🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Health Concern

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in the same week. This drug, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Global Access

According to findings released by a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The research included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in numerous developing nations.

Doctors directly involved have shared optimism. The availability of a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is considered essential to lessen the impact of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.